Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer

Int J Cancer. 2008 Apr 15;122(8):1920-1. doi: 10.1002/ijc.23304.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adenoma / prevention & control
  • Anti-Obesity Agents / administration & dosage
  • Anti-Obesity Agents / adverse effects*
  • Anti-Obesity Agents / pharmacology
  • Apoptosis / drug effects
  • Carcinoma / prevention & control
  • Cell Transformation, Neoplastic / drug effects
  • Colorectal Neoplasms / chemically induced*
  • Colorectal Neoplasms / etiology
  • Colorectal Neoplasms / metabolism
  • Colorectal Neoplasms / prevention & control*
  • Dronabinol / pharmacology
  • Drug Inverse Agonism
  • Humans
  • Inflammatory Bowel Diseases / metabolism
  • Inflammatory Bowel Diseases / pathology
  • Intestinal Mucosa / drug effects*
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / pathology
  • Obesity / complications
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Piperidines / administration & dosage
  • Piperidines / adverse effects*
  • Piperidines / pharmacology
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects*
  • Pyrazoles / pharmacology
  • Receptor, Cannabinoid, CB1 / agonists*
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Receptor, Cannabinoid, CB2 / agonists
  • Receptor, Cannabinoid, CB2 / antagonists & inhibitors
  • Rimonabant

Substances

  • Anti-Obesity Agents
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • Dronabinol
  • Rimonabant